Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 13 of 13
Full-Text Articles in Medicine and Health Sciences
A Randomized,Double-Blind,Placebo-Controlled, Phaseiistudy Of Regorafenib Versus Placebo In Advanced/Metastatic,Treatment-Refractoryliposarcoma: Results From Thesarc024study, R. F. Riedel, K. Ballman, Y. Lu, S. Attia, E. T. Loggers, K. N. Ganjoo, M. B. Livingston, W. Chow, J. Wright, R. G. Maki, +10 Additional Authors
A Randomized,Double-Blind,Placebo-Controlled, Phaseiistudy Of Regorafenib Versus Placebo In Advanced/Metastatic,Treatment-Refractoryliposarcoma: Results From Thesarc024study, R. F. Riedel, K. Ballman, Y. Lu, S. Attia, E. T. Loggers, K. N. Ganjoo, M. B. Livingston, W. Chow, J. Wright, R. G. Maki, +10 Additional Authors
Journal Articles
No abstract provided.
Sarcoma European And Latin American Network (Selnet) Recommendations On Prioritization In Sarcoma Care During The Covid-19 Pandemic, J. Martin-Broto, N. Hindi, S. Aguiar, R. Badilla-Gonzalez, V. Castro-Oliden, M. Chacon, R. Correa-Generoso, E. De Alava, R. Maki, J. Blay, +25 Additional Authors
Sarcoma European And Latin American Network (Selnet) Recommendations On Prioritization In Sarcoma Care During The Covid-19 Pandemic, J. Martin-Broto, N. Hindi, S. Aguiar, R. Badilla-Gonzalez, V. Castro-Oliden, M. Chacon, R. Correa-Generoso, E. De Alava, R. Maki, J. Blay, +25 Additional Authors
Journal Articles
No abstract provided.
Overall Survival And Histology-Specific Subgroup Analyses From A Phase 3, Randomized Controlled Study Of Trabectedin Or Dacarbazine In Patients With Advanced Liposarcoma Or Leiomyosarcoma, S. Patel, M. Von Mehren, D. R. Reed, P. Kaiser, J. Charlson, C. W. Ryan, D. Rushing, M. Livingston, R. G. Maki, G. D. Demetri, +10 Additional Authors
Overall Survival And Histology-Specific Subgroup Analyses From A Phase 3, Randomized Controlled Study Of Trabectedin Or Dacarbazine In Patients With Advanced Liposarcoma Or Leiomyosarcoma, S. Patel, M. Von Mehren, D. R. Reed, P. Kaiser, J. Charlson, C. W. Ryan, D. Rushing, M. Livingston, R. G. Maki, G. D. Demetri, +10 Additional Authors
Journal Articles
No abstract provided.
An Irak1-Pin1 Signalling Axis Drives Intrinsic Tumour Resistance To Radiation Therapy, P. H. Liu, R. B. Shah, Y. Li, A. Arora, P. M. Ung, R. Raman, A. Gorbatenko, S. Kozono, R. G. Maki, S. Sidi, +13 Additional Authors
An Irak1-Pin1 Signalling Axis Drives Intrinsic Tumour Resistance To Radiation Therapy, P. H. Liu, R. B. Shah, Y. Li, A. Arora, P. M. Ung, R. Raman, A. Gorbatenko, S. Kozono, R. G. Maki, S. Sidi, +13 Additional Authors
Journal Articles
No abstract provided.
Eribulin Versus Dacarbazine In Patients With Leiomyosarcoma: Subgroup Analysis From A Phase 3, Open-Label, Randomised Study, J. Blay, P. Schoffski, S. Bauer, A. Krarup-Hansen, C. Benson, D. R. D'Adamo, Y. Jia, R. G. Maki
Eribulin Versus Dacarbazine In Patients With Leiomyosarcoma: Subgroup Analysis From A Phase 3, Open-Label, Randomised Study, J. Blay, P. Schoffski, S. Bauer, A. Krarup-Hansen, C. Benson, D. R. D'Adamo, Y. Jia, R. G. Maki
Journal Articles
No abstract provided.
Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms And Less Complete Recovery At One Year Compared To Unrelated Donors, M. A. Pulsipher, B. R. Logan, D. M. Kiefer, P. Chitphakdithai, M. L. Riches, D. Rizzo, P. Anderlini, R. Bayer, I. Sahdev, B. E. Shaw, +51 Additional Authors
Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms And Less Complete Recovery At One Year Compared To Unrelated Donors, M. A. Pulsipher, B. R. Logan, D. M. Kiefer, P. Chitphakdithai, M. L. Riches, D. Rizzo, P. Anderlini, R. Bayer, I. Sahdev, B. E. Shaw, +51 Additional Authors
Journal Articles
No abstract provided.
Probabilistic Modeling Of Personalized Drug Combinations From Integrated Chemical Screen And Molecular Data In Sarcoma, N. E. Berlow, R. Rikhi, M. Geltzeiler, J. Abraham, M. N. Svalina, L. E. Davis, E. Wise, M. Mancini, R. G. Maki, C. Keller, +19 Additional Authors
Probabilistic Modeling Of Personalized Drug Combinations From Integrated Chemical Screen And Molecular Data In Sarcoma, N. E. Berlow, R. Rikhi, M. Geltzeiler, J. Abraham, M. N. Svalina, L. E. Davis, E. Wise, M. Mancini, R. G. Maki, C. Keller, +19 Additional Authors
Journal Articles
No abstract provided.
A Phase 1 And Randomized Controlled Phase 2 Trial Of The Safety And Efficacy Of The Combination Of Gemcitabine And Docetaxel With Ontuxizumab (Morab-004) In Metastatic Soft-Tissue Sarcomas, R. L. Jones, S. P. Chawla, S. Attia, P. Schoffski, H. Gelderblom, B. Chmielowski, A. Le Cesne, B. A. Van Tine, J. C. Trent, R. G. Maki, +7 Additional Authors
A Phase 1 And Randomized Controlled Phase 2 Trial Of The Safety And Efficacy Of The Combination Of Gemcitabine And Docetaxel With Ontuxizumab (Morab-004) In Metastatic Soft-Tissue Sarcomas, R. L. Jones, S. P. Chawla, S. Attia, P. Schoffski, H. Gelderblom, B. Chmielowski, A. Le Cesne, B. A. Van Tine, J. C. Trent, R. G. Maki, +7 Additional Authors
Journal Articles
No abstract provided.
Oral Curcumin For Radiation Dermatitis: A Urcc Ncorp Study Of 686 Breast Cancer Patients, J. R. Wolf, C. E. Heckler, J. J. Guido, A. R. Peoples, J. S. Gewandter, M. Ling, V. P. Vinciguerra, T. Anderson, L. Evans, G. R. Morrow, +2 Additional Authors
Oral Curcumin For Radiation Dermatitis: A Urcc Ncorp Study Of 686 Breast Cancer Patients, J. R. Wolf, C. E. Heckler, J. J. Guido, A. R. Peoples, J. S. Gewandter, M. Ling, V. P. Vinciguerra, T. Anderson, L. Evans, G. R. Morrow, +2 Additional Authors
Journal Articles
No abstract provided.
Bi-Specific And Tri-Specific Antibodies- The Next Big Thing In Solid Tumor Therapeutics, K. Runcie, D. R. Budman, V. John, N. Seetharamu
Bi-Specific And Tri-Specific Antibodies- The Next Big Thing In Solid Tumor Therapeutics, K. Runcie, D. R. Budman, V. John, N. Seetharamu
Journal Articles
No abstract provided.
Extended Follow-Up And Impact Of High-Risk Prognostic Factors From The Phase 3 Resonate Study In Patients With Previously Treated Cll/Sll, J. R. Brown, P. Hillmen, S. O'Brien, J. C. Barrientos, N. M. Reddy, S. E. Coutre, C. S. Tam, S. P. Mulligan, U. Jaeger, J. C. Byrd, +20 Additional Authors
Extended Follow-Up And Impact Of High-Risk Prognostic Factors From The Phase 3 Resonate Study In Patients With Previously Treated Cll/Sll, J. R. Brown, P. Hillmen, S. O'Brien, J. C. Barrientos, N. M. Reddy, S. E. Coutre, C. S. Tam, S. P. Mulligan, U. Jaeger, J. C. Byrd, +20 Additional Authors
Journal Articles
No abstract provided.
Activity Of Pazopanib And Trabectedin In Advanced Alveolar Soft Part Sarcoma, S. Stacchiotti, O. Mir, A. Le Cesne, B. Vincenzi, A. Fedenko, R. G. Maki, N. Somaiah, S. Patel, M. Brahmi, A. Kawai, +13 Additional Authors
Activity Of Pazopanib And Trabectedin In Advanced Alveolar Soft Part Sarcoma, S. Stacchiotti, O. Mir, A. Le Cesne, B. Vincenzi, A. Fedenko, R. G. Maki, N. Somaiah, S. Patel, M. Brahmi, A. Kawai, +13 Additional Authors
Journal Articles
No abstract provided.
Repurposing Mebendazole As A Replacement For Vincristine For The Treatment Of Brain Tumors, M. De Witt, A. Gamble, D. Hanson, D. Markowitz, C. Powell, S. Al Dimassi, M. Atlas, J. Boockvar, R. Ruggieri, M. Symons
Repurposing Mebendazole As A Replacement For Vincristine For The Treatment Of Brain Tumors, M. De Witt, A. Gamble, D. Hanson, D. Markowitz, C. Powell, S. Al Dimassi, M. Atlas, J. Boockvar, R. Ruggieri, M. Symons
Journal Articles
No abstract provided.